(914) 315-9334
Global Phase 3: Cancer Stemness Inhibitor in mCRC
October 21, 2016

Boston Biomedical Initiates CanStem303C: A Global Phase III Study Investigating Cancer Stemness Inhibitor Napabucasin in Patients With Pretreated Advanced Colorectal Cancer

Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stemness pathways, today announced dosing of the first patient in CanStem303C, a new global Phase III study investigating napabucasin in combination with standard of care (FOLFIRI) in patients with previously treated metastatic colorectal carcinoma (mCRC).

About Cancer Stem Cells

Cancer stem cells (CSCs) exhibit stemness – the ability to self-renew and differentiate into heterogeneous cancer cells. This allows the CSCs to act like seeds, causing a patient’s cancer to relapse or spread within their body. Evidence suggests that these cells possess resistance to conventional chemotherapy and radiation, so while such treatments can successfully shrink tumors, a population of CSCs may still survive.

Boston Biomedical is leading the biopharmaceutical industry in the development of novel compounds designed to target cancer stemness pathways, with the goal of addressing stemness, an ongoing challenge in cancer treatment.

“Early clinical data for napabucasin in combination with FOLFIRI in advanced colorectal cancer has demonstrated encouraging anti-tumor activity even in FOLFIRI-pretreated patients, so we are eager to understand more deeply its potential therapeutic benefits in this difficult-to-treat cancer,” said Chiang J. Li, M.D. FACP, President, CEO and Chief Medical Officer of Boston Biomedical, and the Head of Global Oncology for Sumitomo Dainippon Pharma Group. “This milestone study is evidence of our commitment to uncover the full potential of cancer stemness pathway inhibition, and develop innovative second-line options for the colorectal cancer patient population.”

“Cancer stem cells are known to be resistant to traditional therapies such as chemotherapy and radiation, and represent a more therapeutically challenging subgroup of cancer cells,” said Axel Grothey, M.D., Professor of Oncology, Mayo Clinic in Rochester, MN. “Therefore, the opportunity to investigate the addition of a cancer stemness inhibitor to established chemotherapeutic regimens in colorectal cancer research is attractive to clinicians seeking to improve long-term outcomes for metastatic colorectal cancer patients.”